Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 50 clinical trials
Featured trial
Sickle Cell Disease Research Study - Fulcrum Therapeutics  

The purpose of this study is to determine the safety and clinical effects of SCD-101 when given to adults with sickle cell disease.

thalassemia
hemoglobin f
  • 1203 views
  • 18 Apr, 2022
  • 4 locations
Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance (SURPASS ET)

This is a Phase 3 open-label, multicenter, randomized, active-controlled study designed to compare the efficacy and safety and tolerability of P1101 compared with ANA after 12 months of treatment as second-line therapy for subjects with ET who have had a suboptimal or failed response to HU.

thrombocytosis
platelet count
anagrelide
neutrophil count
hydroxyurea
  • 0 views
  • 25 Mar, 2022
  • 57 locations
A Trial for Prevention of Recurrent Ischemic Priapism in Men With Sickle Cell Disease: A Pilot Study (PIN)

enroll a minimum of 30 participants and a maximum of 200 participants. Study investigators hypothesize that hydroxyurea therapy combined with tadalafil is superior to a combination of hydroxyurea and

  • 0 views
  • 29 Apr, 2022
  • 1 location
A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera (VERIFY)

The study is designed to evaluate the safety and efficacy of rusfertide in subjects with polycythemia vera (PV) in maintaining hematocrit control and in improving symptoms of PV.

phlebotomy
jak2 v617f
  • 0 views
  • 19 Apr, 2022
  • 2 locations
Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia (FAST)

ratio of aspirin maintenance in high risk Essential thrombocythemia (ET) patients, in hematological response (modified by amendment 1/03/2017) on Hydroxyurea.

hydroxyurea
thrombocytosis
essential thrombocythemia
thrombosis
aspirin
  • 3 views
  • 23 Feb, 2022
  • 1 location
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis (PACIFICA)

This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician's choice (P/C) therapy in patients with MF and severe thrombocytopenia (platelet count <50,000/μL). Approximately 348 patients in total will be enrolled, randomized 2:1 to either pacritinib (approximately 232 patients) or …

blast cells
thrombocytopenia
platelet count
international normalized ratio
pacritinib
  • 698 views
  • 23 Apr, 2022
  • 74 locations
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions (INDEPENDENCE)

The purpose of this Phase 3 study is to evaluate the efficacy and safety of Luspatercept compared with placebo in subjects with myeloproliferative neoplasm (MPN)-associated Myelofibrosis (MF) and anemia on concomitant Janus kinase 2 (JAK2) inhibitor therapy and who require red blood cell count (RBC) transfusions. The study is divided …

bilateral oophorectomy
cancer
anemia
vasectomy
  • 28 views
  • 05 May, 2022
  • 124 locations
Hydroxyurea Optimization Through Precision Study (HOPS)

Hydroxyurea Optimization through Precision Study (HOPS) is a prospective, multi-center, randomized trial that will directly compare a novel, individualized dosing strategy of hydroxyurea to

hydroxyurea
thalassemia
sickle hemoglobin
hemoglobin f
anemia
  • 82 views
  • 10 Feb, 2022
  • 12 locations
Hydroxyurea Therapy: Optimizing Access in Pediatric Populations Everywhere

"Pharmacokinetics and Bioavailability of a Liquid Formulation of Hydroxyurea in Pediatric Patients with Sickle Cell Anemia" (NCT01506544) trial. Exploratory Objectives: Capture information regarding

hydroxyurea
hydroxyurea oral capsule
anemia
schwartz
body mass index
  • 35 views
  • 04 Feb, 2022
  • 1 location
Therapeutic Response Evaluation and Adherence Trial (TREAT) (TREAT)

The primary objectives of this prospective study of hydroxyurea for children with sickle cell anemia are 1) Develop and prospectively evaluate a population pharmacokinetic/pharmacodynamics model

hydroxyurea
thalassemia
anemia
  • 20 views
  • 26 Jan, 2022
  • 1 location